Tamtam Try Tamtam free
BioMarin Pharmaceutical Inc. logo

BioMarin Pharmaceutical Inc. account plan

Developing genetic therapies

At a glance

BioMarin is a San Rafael, California rare disease biotech with nine commercial therapies; FY2025 total revenues were $3,221.3 million.

BioMarin Pharmaceutical is a global rare disease biotechnology company founded in 1997 and based in San Rafael, California, developing medicines for genetically defined conditions. It sells through specialty pharmacies, hospitals, government agencies and distributors, with a direct sales force in the U.S., Europe, South America and other significant markets. FY2025 total revenues were $3,221.3 million and net income $348.9 million; it had 3,221 employees at December 31, 2025. After acquiring Amicus Therapeutics on April 27, 2026 it counts nine commercial therapies, grouped as VOXZOGO (Skeletal Conditions) and Metabolic Conditions.

Business units

Strategic priorities

Integrate Amicus Therapeutics
Amicus was acquired on April 27, 2026 for about $5.3 billion; BioMarin expects about $220 million of non-GAAP cost synergies fully realized in 2028, and synergy delivery is ahead of schedule.
Extend VOXZOGO beyond achondroplasia
PDUFA dates of February 28, 2027 for full approval in achondroplasia and May 30, 2027 for hypochondroplasia, an estimated global addressable population of about 14 thousand children.
Grow Galafold and Pombiliti + Opfolda
Drive diagnosis, treatment and switching in Fabry and Pompe; peak revenue of roughly $1 billion each was reiterated, with potential to be higher.
Clinical-stage business development
Five deals in two years, with further deals focused on clinical-stage assets in genetics that fit the Skeletal Conditions and Metabolic Conditions business units.
Next-generation pipeline
BMN 333 (longer-acting CNP aiming for superiority over VOXZOGO), BMN 450 (potential first subcutaneous Fabry enzyme therapy) and BMN 440 (oral therapy for hypophosphatasia, data in 2027).

Latest results

Q3 2026 total revenues were $1,024.6 million against $776.1 million in Q3 2025, the first quarter above $1 billion in the company's history. The quarter was a net loss of $122.8 million, driven by $287.7 million of acquired IPR&D for BMN 440, $99.5 million of intangible amortization and $55.6 million of interest expense; nine-month net income was $27.5 million. Gross margin was 80.0% (81.9% a year earlier). FY2026 revenue guidance was cut to $3.8-3.9 billion because one international customer intends to defer about $70 million of orders and Middle East customer liquidity has worsened; non-GAAP EPS guidance is $2.80-3.10.

Investments and deals

Amicus Therapeutics acquisition
Closed April 27, 2026 for about $5.3 billion, funded with the $850.0 million 2034 Notes, term loans and about $1.7 billion of cash; adds GALAFOLD and POMBILITI + OPFOLDA.
Alesta Therapeutics acquisition
Acquired August 31, 2026 for $303.4 million plus up to $215 million of milestones, adding oral BMN 440 for hypophosphatasia.
BMN 450 license
Exclusive worldwide license from GC Biopharma and Hanmi in October 2026 for a long-acting Fabry enzyme therapy: $70.0 million upfront and up to $405.0 million of milestones.
Inozyme acquisition and BMN 401
Inozyme was acquired in July 2025 for $285.2 million net cash; BMN 401 development was discontinued across all indications in August 2026.
ROCTAVIAN withdrawal
Voluntary market withdrawal of the hemophilia A gene therapy decided in December 2025, with about $240.0 million of restructuring charges.

Challenges and risks

Higher debt
Indebtedness of about $4.2 billion at September 30, 2026, including $600.0 million of convertible notes due May 2027 to refinance, and cash down to $736.0 million.
VOXZOGO competition
A competitor entered the U.S. market in 2026; BioMarin settled all patent litigation with Ascendis in September 2026 in exchange for royalties.
Lumpy international orders
Two thirds of the business is outside the U.S., largely national health systems that order irregularly; one customer's deferral of about $70 million of orders cut 2026 guidance.
Pricing and trade pressure
Government price controls and the Inflation Reduction Act may lower prices; tariffs, currency and Middle East disruption are named risks.
Manufacturing and supply
Reliance on contract manufacturers and sole-source materials; a $31 million charge in Q1 2026 came from an unsuccessful process qualification campaign for NAGLAZYME.

What leadership says

“32% year over year growth in the third quarter. Surpassing $1 billion in quarterly revenues for the first time in our history.”

Alexander Hardy, Chief Executive Officer · BioMarin Q3 2026 earnings call, 2026-11-02

“Continue to remain focused on clinical stage deals at the moment”

Alexander Hardy, Chief Executive Officer · BioMarin Q3 2026 earnings call, 2026-11-02

“this guidance change is not driven by patient demand in these markets.”

Brian Mueller, Chief Financial Officer · BioMarin Q3 2026 earnings call, 2026-11-02

“Our goal with BMN 333 is to evolve this space, not just make a more convenient version”

Gregory Friberg, Chief R&D Officer · BioMarin Q1 2026 earnings call, 2026-05-04

Where a supplier can help

Integration and synergy delivery
Tied to the Amicus integration and its cost synergy target for 2028: systems consolidation, finance, HR and commercial operations support help merge two organizations.
Rare disease diagnosis and patient finding
Tied to growing Galafold, Pombiliti + Opfolda and VOXZOGO in hypochondroplasia, where diagnosis is the main lever: data, patient-identification and medical education partners fit.
Manufacturing and supply chain resilience
Tied to the manufacturing and supply challenge: contract manufacturing, process qualification and quality services address a named risk and the NAGLAZYME charge.
Launch readiness for 2027 PDUFA dates
Tied to the VOXZOGO expansion priority: market access, pricing and launch operations ahead of the February 28, 2027 and May 30, 2027 decisions.
Treasury and international order management
Tied to the higher debt and lumpy international orders: forecasting, credit risk and currency tools help manage government customers and refinancing.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like BioMarin Pharmaceutical Inc.?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about BioMarin Pharmaceutical Inc.

What does BioMarin Pharmaceutical do?

BioMarin develops and sells medicines for rare, genetically defined diseases, including VOXZOGO for achondroplasia and enzyme therapies such as VIMIZIM, NAGLAZYME, PALYNZIQ and GALAFOLD.

What is BioMarin's revenue?

FY2025 total revenues were $3,221.3 million. Q3 2026 revenues were $1,024.6 million, and FY2026 guidance is $3.8-3.9 billion.

How many employees does BioMarin have?

BioMarin had 3,221 employees at December 31, 2025, of which 2,026 in the U.S. and Canada and 1,195 outside North America, before the Amicus acquisition.

What is BioMarin's strategy?

Grow in rare disease through internal research and acquisitions, organized around Skeletal Conditions and Metabolic Conditions, integrate Amicus and extend VOXZOGO to new short-stature conditions.

Who leads BioMarin?

Alexander Hardy is Chief Executive Officer and Brian Mueller is Chief Financial Officer; Cristin Hubbard is Chief Commercial Officer and Gregory Friberg is Chief R&D Officer.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)